Professional Documents
Culture Documents
Acute respiratory
infections 4.4 million HIV/AIDS >1 million
2/
GE /
Vaccine development
1950- Most vaccines produced used traditional technology for past 40 yrs
1982 Plasma derived Hepatitis B Vaccine
1985 Hib was licensed by Praxis, Rochester, NY
1986 Recombinant Hepatitis B Vaccine - Merck
Mid 80- New vaccines from advances in Mol. Biol., Immunology, production tech
90s and drug delivery system. 14 new or improved vaccines developed
1997 International Vaccine Institute, Seoul, S. Korea
1999 AIDS vaccine finished phase III clinical trial in USA, started trial in Asia
98-2000 8 new vaccines expected, 4 potentials to prevent rotavirus, enterotoxic
Escherichia coli (ETEC) or cholera, pneumococcal pneumonia & meningococcal diseases
Vaccine Market
1985 US$ 300m
1996 US$ 4,000m
2000 US$ 7,000m
3/
GE /
Vaccine development
New Vaccine Strategies
4/
GE /
The Vaccine Market
The Vaccine Market
The Market Leader
SmithKline Beecham 33% Market
Vaccines Sales 1996 US$ 996m
HBV, Enegerix-B US$ 568m
HAV, Harvix(1996 in China) US$ 256m
Infanrix (DPT)
5/
GE /
The Vaccine Market
The Vaccine Market
6/
GE /
The Vaccine Market
The Vaccine Market
7/
GE /
Vaccine Report
Vaccine Development
ccines Product in Development
mpany Plan/R&D Preclinical Phase I Phase II Phase IIIa Phase IIIb Marketed Annual Market
Sales share
ithkline EBV Campylobacter MMR-Varicella DTPaHepBHiB DTPa, Harvix US$996m 33%
cham Otitis media / Helicobacter Improved DTPaIPVHepBHib DTPa Hib (Hepatitis A) in 1996
MeningitisA/C pylori Hepatitis A/A&B Enegerix
ccines Acellular Pertussis Hepatitis A&B (Hepatitis B)
RSV comb. adults (Twinrix) Infanrix
Lyme Disease MMR , Varicella (Varilix) (diphtheria,
HSV, Cholera DTPwHepB tetanus and
Enterotoxigenic E. Coli pertussis
Salmonella Thypi vaccine)
DTPaHepB
DTPaIPVHiB
ithkline Melanoma Human Papilloma
cham Herpes Simplex Virus
munothera Hepatitis B
tic
cines
teur Pox virus Combination Lyme around 20%
rieux vector Pediatric 600 mUSD
nnaught construct Meningitis
(conjugate)
Pneumococcal
(conjugate)
Influenza
(improved)
rck Sharpe 663 MUSD 22%
Dohme
8/
GE /
Vaccine development
Targets for new vaccines
9/
GE /
Vaccine development
Vs diseases in developing countries
Table 2. Summary of the status of vaccine development and use against the major
diseases in developing countries.
11 /
GE /
Vaccine Market
12 /
GE /
Vaccine Production with Microcarriers
13 /
GE /
Microporous carriers: Cytodex
14 /
GE /
Cytodex production examples
Smith Kline: Vero cells, polio virus, Cytodex 3, cell density up to 14,5 million
/ml, virus titer up to 10 power 10,13 TCID50/ml.
Adv. Anim. Cell-Biol. Technol. Bioprocesses (1989), High density microcarrier culture for
viral vaccine production.
15 /
GE /
Macroporous carriers: Cytopore
Substitution macroporous particle
DEAE (1.0, 1.85 meq/g) throughout
matrix
Much higher surface area-1.1M2
/gram
Give protection from stirrer, spin
filter and air/O2 sparging Porous
structure of
Give higher cell densities Cytopore
16 /
GE /
Cytopore production examples
3800
4000
3500 3200
3000
2500
2000
1800
2000
IL-4 ug/12 days
1500
1000
500
0
Cytopore (10% Suspension Cytopore (S.F.) Suspension
CS) (10% CS) (S.F.)
17 /
GE /
Microcarriers in roller bottles
18 /
GE /
Vaccine Downstream Purification
Gel filtration method on
Sepharose 4,6FF in BPG
or INdEX Albumin, phenol red, impurities
High degree of
automation, sanitary,
reproducible, simple
19 /
GE /
Vaccine Downstream Purification at large scale
20 /
GE /
1st rDrug Using STL
Approved by FDA
• SKB,a lipoprotein, human vaccine
• Direct capture on STL400 after
high pressure homogenization of
E.coli. Combining 3 steps into 1.
• Further purified on two Sepharose
IEX and Sephacryl in Chromaflow
21 /
GE /